Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 2 |
Infectious Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Inactivated vaccine | 1 |
Diagnostic radiopharmaceuticals | 1 |
Synthetic peptide | 1 |
Small molecule drug | 1 |
Prophylactic vaccine | 1 |
Top 5 Target | Count |
---|---|
GnRHR(Gonadotropin-releasing hormone receptor) | 1 |
Target |
Mechanism AR agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date29 Sep 1995 |
Target |
Mechanism ATP7A modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jan 2026 |
Sponsor / Collaborator |
Start Date01 Dec 2025 |
Sponsor / Collaborator |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
[18F]-6F-DA | Endocrine System Diseases More | Phase 1 |
BB IND-6989 | Typhoid Fever More | Phase 1 |
Gonadotropin releasing hormone(Eunice Kennedy Shriver National Institute Of Child Health And Human Development) ( GnRHR ) | Hypogonadism More | Clinical |
Brefeldin A | - | Preclinical |
Shigella sonnei-rEPA vaccine(Eunice Kennedy Shriver National Institute Of Child Health And Human Development) | Dysentery, Bacillary More | Discontinued |